The $15 Billion Question Hanging Over Biotech's Future

If you're keeping score, that's a lot of demolition paired with one new construction project.

Why Biotech Should (and Shouldn't) Panic

Let's talk about the FDA, since that's the agency that actually approves drugs. The budget proposal doesn't spell out a specific FDA funding number, which is both curious and telling. About 45-50% of the FDA's budget comes from user fees paid by pharmaceutical companies, not congressional appropriations. So even in a worst-case scenario, the drug review machinery has its own revenue stream.

That said, the indirect effects could be brutal. NIH funds the preclinical research (the early-stage lab work that figures out whether a drug concept even makes sense) that feeds the entire biotech pipeline. Cut that funding, and you're not just canceling today's grants; you're hollowing out the discoveries that would have become tomorrow's blockbuster drugs.

The Congressional Budget Office has studied this exact question. Their finding: a permanent 10% reduction in NIH funding would lead to fewer drugs reaching the market. The impact would compound over time, taking full effect roughly 30 years after the cuts began. It's the biotech equivalent of eating your seed corn.

Congress Will Probably Say No (Again)

Before you start doom-scrolling, here's some important context: presidential budget proposals almost never survive Congress intact. They're more like opening bids in a negotiation than actual spending plans.

Last year's budget proposed even deeper HHS cuts (26.2%, or down to $93.8 billion), and Congress essentially laughed it off. Lawmakers not only rejected the cuts but actually increased NIH funding to $48.7 billion. Bipartisan support for medical research has been one of the most durable coalitions in Washington for decades.

Advocacy groups like United for Medical Research are already lobbying hard. The appropriations process won't wrap up until closer to October 1, when FY2027 begins, giving both sides plenty of time to negotiate.

The Real Damage Is Already Happening

But here's what the "Congress will fix it" argument misses: uncertainty itself is corrosive. Even proposals that never become law can reshape behavior.

We've already seen this movie. In FY2025, roughly 2,300 NIH grants totaling nearly $2.5 billion were terminated, including at least 160 active clinical trials in cancer, HIV/AIDS, and chronic diseases. University labs have frozen hiring. Postdocs (the young scientists who do much of the actual bench work) are looking at careers in consulting instead of curing disease.

When HHS canceled nearly $500 million in mRNA vaccine development contracts last August, it sent a signal that rippled far beyond the specific programs affected. Researchers and biotech startups need to plan years in advance. If they can't trust that federal funding will be there when a five-year grant is supposed to pay out, they'll pursue safer, shorter-term projects. Or they'll leave the field entirely.

That's the hidden cost no budget document captures. You can measure dollars cut; you can't easily measure the brilliant researcher who decided to go into finance instead.

What Happens Next

The ball is now in Congress's court. House and Senate appropriations committees will hold hearings, mark up their own spending bills, and likely produce something that looks very different from what the White House proposed. If history is any guide, NIH funding will hold steady or even inch upward.

But "history as a guide" requires Congress to actually pass appropriations bills on time, something it hasn't consistently managed in years. A continuing resolution (essentially keeping last year's spending levels on autopilot) is the most likely short-term outcome, which would at least prevent cuts from taking effect immediately.

For biotech investors and executives, the playbook hasn't changed: watch Congress, not the White House. The president proposes; the legislature disposes. The real risk isn't this budget. It's the slow erosion of confidence that comes from having this same fight, year after year, while the rest of the world keeps investing in science.

Inside Big Pharma's Tariff Escape Hatch

The Trump administration just announced 100% tariffs on imported brand-name drugs, but the fine print tells a very different story. With 13 companies already cutting confidential deals and generics completely exempt, analysts say only 4.4% of pharma imports will actually face the full rate.